Compare CXDO & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXDO | ELUT |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | 26 |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.1M | 45.8M |
| IPO Year | 1999 | 2020 |
| Metric | CXDO | ELUT |
|---|---|---|
| Price | $6.17 | $1.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $9.25 | $6.00 |
| AVG Volume (30 Days) | ★ 210.9K | 157.8K |
| Earning Date | 03-03-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 166.67 | 146.77 |
| EPS | 0.16 | ★ 0.87 |
| Revenue | ★ $68,167,000.00 | $12,293,000.00 |
| Revenue This Year | $38.52 | N/A |
| Revenue Next Year | $19.22 | $10.83 |
| P/E Ratio | $39.75 | ★ $1.23 |
| Revenue Growth | ★ 12.05 | N/A |
| 52 Week Low | $3.75 | $0.50 |
| 52 Week High | $7.80 | $2.99 |
| Indicator | CXDO | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 47.72 |
| Support Level | $6.08 | $0.86 |
| Resistance Level | $6.73 | $1.15 |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 9.52 | 20.00 |
Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support, and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of its revenue from the Cloud telecommunications segment.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.